Relmada Therapeutics, Inc. (RLMD)
RLMD moved a median of -0.01% 30 minutes after news, and -0.66% by the close. How RLMD actually reacts to news — the realized, point-in-time move the market made, measured across 265 labeled events over the last three years with zero look-ahead.
RLMD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 255 |
| 30-min | -0.01% | 44% | 264 |
| 60-min | 0.00% | 46% | 264 |
| to close | -0.66% | 41% | 265 |
| Middle 50% of RLMD reactions | -2.02% to +2.03% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 265 |
Half of all Relmada Therapeutics, Inc. news events land between -2.02% and +2.03% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RLMD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | -0.70% | 42% | -7.91% |
| Coverage initiations | 11 | -0.74% | 18% | -0.15% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how RLMD ranks against every other measured name →
That’s how RLMD usually reacts — get an email when it moves on news →Email me when RLMD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RLMD's baseline. Nothing else.
Recent RLMD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K RELMADA THERAPEUTICS, For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | -3.41% | |
| Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference | Press release | GlobeNewswire | +0.93% | +3.48% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.77% | -10.99% | |
| Form 8-K RELMADA THERAPEUTICS, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -5.77% | -10.99% | |
| Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -5.77% | -10.99% | |
| Form 8-K RELMADA THERAPEUTICS, For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | +1.55% | |
| Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer | Press release | GlobeNewswire | +0.29% | +1.55% | |
| Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | Press release | GlobeNewswire | -1.76% | -12.64% | |
| Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes | Press release | GlobeNewswire | -0.76% | +5.60% | |
| Form S-8 RELMADA THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | +1.04% | +2.07% | |
| Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program | Press release | GlobeNewswire | -1.01% | +1.40% | |
| Form 8-K RELMADA THERAPEUTICS, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | +0.14% | |
| Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -0.48% | -0.14% | |
| Form S-3ASR RELMADA THERAPEUTICS, | SEC filing · Form S-3ASR | SEC EDGAR | -1.33% | -1.07% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.07% | +0.54% | |
| Form 8-K RELMADA THERAPEUTICS, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +0.54% | |
| Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.07% | +0.54% | |
| Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026 | Press release | GlobeNewswire | -0.67% | +5.93% | |
| Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 | Press release | GlobeNewswire | +0.94% | -1.87% | |
| Form DEF 14A RELMADA THERAPEUTICS, For: May 27 | SEC filing · Form DEF | SEC EDGAR | -0.54% | -1.34% | |
| Form DEFA14A RELMADA THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | -0.54% | -1.34% | |
| Form EFFECT RELMADA THERAPEUTICS, | SEC filing · Form EFFECT | SEC EDGAR | -1.17% | -5.57% | |
| Form PRE 14A RELMADA THERAPEUTICS, For: Apr 06 | SEC filing · Form PRE | SEC EDGAR | -1.47% | -0.73% | |
| Form S-3 RELMADA THERAPEUTICS, | SEC filing · Form S-3 | SEC EDGAR | +1.74% | +0.29% | |
| Form 8-K RELMADA THERAPEUTICS, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -1.98% | -3.46% | |
| Form 10-K RELMADA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.23% | -6.62% | |
| Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update | Press release | GlobeNewswire | -1.23% | -6.62% | |
| Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 | Press release | GlobeNewswire | -1.56% | -1.28% | |
| Form 8-K RELMADA THERAPEUTICS, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | -1.86% | +11.16% | |
| Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing | Press release | GlobeNewswire | -1.86% | +11.16% | |
| Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer | Press release | GlobeNewswire | -1.86% | +11.16% | |
| Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference | Press release | GlobeNewswire | +7.61% | -3.36% | |
| Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders | Press release | PR Newswire | -0.22% | +3.84% | |
| Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications | Press release | GlobeNewswire | -2.09% | -4.64% | |
| Form 8-K RELMADA THERAPEUTICS, For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.83% | |
| Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology | Press release | GlobeNewswire | -0.25% | +0.25% | |
| Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 | Press release | GlobeNewswire | -4.23% | +1.92% | |
| Form 8-K RELMADA THERAPEUTICS, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +5.10% | -1.57% | |
| Form 8-K RELMADA THERAPEUTICS, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | +25.34% | |
| Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer | Press release | GlobeNewswire | -0.45% | +25.34% | |
| Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -0.45% | +25.34% | |
| Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 | Press release | GlobeNewswire | -0.94% | -6.13% | |
| Form 8-K RELMADA THERAPEUTICS, For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | -0.61% | -7.36% | |
| Form 8-K RELMADA THERAPEUTICS, For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +7.06% | -5.88% | |
| Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | +7.06% | -5.88% | |
| Form 8-K RELMADA THERAPEUTICS, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +3.21% | |
| Relmada Issues Mid-Year CEO Letter to Shareholders | Press release | GlobeNewswire | +0.32% | +3.21% | |
| Form 8-K RELMADA THERAPEUTICS, For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | -2.14% | +25.66% | |
| Form 10-Q RELMADA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.77% | -1.28% | |
| Form 8-K RELMADA THERAPEUTICS, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.77% | -1.28% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RLMD section they belong to.
Where else RLMD is measured.
RLMD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EVOTEC AG S/ADR (EVTCY) | 265 | 0.00% | 17% |
| MiMedx Group, Inc (MDXG) | 265 | +0.14% | 57% |
| HUTCHMED (China) Limited - American Depositary Shares (HCM) | 263 | 0.00% | 47% |
| iBio, Inc. (IBIO) | 263 | -0.38% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Relmada Therapeutics, Inc.'s median reaction calculated?
Every labeled RLMD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 265 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of RLMD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RLMD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.